Hyperuricemia
Navigation Links
Hyperuricemia in Medical News
FDA approves ULORIC (febuxostat) for the chronic management of hyperuricemia in patients with gout
... 40 mg and 80 mg for the chronic management of hyperuricemia in patients with gout. This once-daily, oral ... for the more than five million patients who have hyperuricemia associated with gout. ULORIC was discovered by ... offers clinicians and their patients who have hyperuricemia associated with gout a new treatment option that ...... Center in Philadelphia, Pennsylvania. "Untreated gout and prolonged hyperuricemia can lead to an accumulation of needle-like urate crystals that not only ... to reduce urate crystal accumulation and prevent the consequences of hyperuricemia and gout. It is important to work with your physician to monitor ...
AUA 2008: Uric acid stones may indicate arteriosclerotic diseases
... and urinary stone disease and concluded that arteriosclerotic diseases and hyperuricemia can be predictors of uric acid stones. 77.5 percent of all patients in ... 2 diabetes, but the proportion of uric acid stones in elderly men with hyperuricemia and arteriosclerotic disease was significantly higher. Metabolic ...... people with gout should not interpret a lack of symptoms as a "cure." Even when painful symptoms are not present, untreated gout and prolonged hyperuricemia can lead to permanent joint damage and deformity. Most experts agree that lowering a person's uric acid level to less than 6.0 mg/dL is helpful to ...
Review of Takeda's Febuxostat New Drug Application Continues Past PDUFA Date
... look forward to receiving a final approval date for febuxostat." Febuxostat is currently under review with FDA for once-daily, oral treatment of hyperuricemia in patients with gout. The NDA for febuxostat included data from multiple clinical trials involving more than 4,000 patients. In November 2008, ...Pegloticase BLA Filing Accepted for Priority Review by FDA
... ABOUT PEGLOTICASE Pegloticase (formerly referred to as Puricase(R)) is a pegylated recombinant mammalian urate oxidase in development to control hyperuricemia and its clinical consequences in patients for whom conventional therapy is contraindicated or has been ineffective. The two Phase 3 pivotal trials ...Basketball Star Details His Struggle With Gout
... Americans, and to debunk stereotypes about the so-called "disease of kings." According to GUAES, gouty arthritis results from a condition known as hyperuricemia -- the build-up of abnormally high levels of uric acid in the blood. A normal waste product that forms from the breakdown of purines found in cells ...Risk Of Heart Attack Increased By Gout
... up of uric acid in blood. When chronic or severe hyperuricemia leads to urate crystals within joints, it results ... Blood Institute. There were 5,337 men with hyperuricemia at the beginning of the study. Over the study ... atherogenesis and thrombogenesis is needed. hyperuricemia is well known to be an independent risk factor ...Hyperuricemia in Medical Technology
... the FDA approve febuxostat for the treatment of hyperuricemia in patients with gout. The vote was 12 to zero in ... be the first new treatment for the management of hyperuricemia associated with gout in more than 40 years.
... approval of febuxostat for the treatment of hyperuricemia in patients with gout, is a positive step in ...
... clinical efficacy study in gout patients with hyperuricemia in the first half of 2008. The Company is ... approved by the FDA for the treatment of hyperuricemia associated with gout in the past 40 years, ... 8% experienced serious adverse events (1). hyperuricemia in HIV There is a high prevalence ...
... (p=0.0012). The PUA response rate among patients with baseline hyperuricemia defined as plasma uric acid >7.5mg/dL was 90% with Elitek versus 53% ... at either high or potential risk for TLS: High risk for TLS was defined as hyperuricemia from the cancer at baseline (plasma uric acid >7.5 mg/dL), very ...
... dizziness (3% vs 1%) -- AEs reported in >2% of patients taking BENICAR HCT(R) and more frequently than placebo included nausea (3% vs 0%), hyperuricemia (4% vs 2%), dizziness (9% vs 2%), and upper respiratory tract infection (7% vs 0%) Dosing and Administration No initial dosage ...
... was dizziness (3% vs 1%) -- AEs reported in > 2% of patients taking BENICAR HCT and more frequently than placebo included nausea (3% vs 0%), hyperuricemia (4% vs 2%), dizziness (9% vs 2%), and upper respiratory tract infection (7% vs 0%) Dosing and Administration -- No initial dosage adjustments ...
... vs 1 percent). AEs reported in > 2 percent of patients taking BENICAR HCT and more frequently than placebo included nausea (3 percent vs 0 percent), hyperuricemia (4 percent vs 2 percent), dizziness (9 percent vs 2 percent), and upper respiratory tract infection (7 percent vs 0 percent). No initial dosage ...
... clinical efficacy study in gout patients with hyperuricemia in the first half of 2008. The Company is ... approved by the FDA for the treatment of hyperuricemia associated with gout in the past 40 years, ... 8% experienced serious adverse events (1). hyperuricemia in HIV There is a high prevalence ...
... (p=0.0012). The PUA response rate among patients with baseline hyperuricemia defined as plasma uric acid >7.5mg/dL was 90% with Elitek versus 53% ... at either high or potential risk for TLS: High risk for TLS was defined as hyperuricemia from the cancer at baseline (plasma uric acid >7.5 mg/dL), very ...
Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
... Doses of RDEA806, A Novel Prodrug for the Potential Treatment of hyperuricemia Location: Le Palais de Congres de Paris - Level 1 (Abstract # THU0356) ... No new therapies have been approved by the FDA for the treatment of hyperuricemia associated with gout in the past 40 years. About RDEA594 RDEA594 is a ...... dizziness (3% vs 1%) -- AEs reported in >2% of patients taking BENICAR HCT(R) and more frequently than placebo included nausea (3% vs 0%), hyperuricemia (4% vs 2%), dizziness (9% vs 2%), and upper respiratory tract infection (7% vs 0%) Dosing and Administration No initial dosage ...
New Report by BioTrends Research Group to Highlight the Launch of ULORIC(R) (febuxostat)
... received FDA approval for Uloric (R) (generic name: febuxostat) on February 13, 2009. Uloric (R) is indicated for the chronic management of hyperuricemia associated with gout and represents the first product for gout that has been approved in over forty years. LaunchTrends(TM): Uloric (R) ...Savient Provides Update on Pegloticase BLA
... KRYSTEXXA (pegloticase) (formerly referred to as Puricase(R)) is a pegylated recombinant mammalian urate oxidase in development to control hyperuricemia and its clinical consequences in patients for whom conventional therapy is contraindicated or has been ineffective. The two Phase 3 pivotal trials ...... was dizziness (3% vs 1%) -- AEs reported in > 2% of patients taking BENICAR HCT and more frequently than placebo included nausea (3% vs 0%), hyperuricemia (4% vs 2%), dizziness (9% vs 2%), and upper respiratory tract infection (7% vs 0%) Dosing and Administration -- No initial dosage adjustments ...
... vs 1 percent). AEs reported in > 2 percent of patients taking BENICAR HCT and more frequently than placebo included nausea (3 percent vs 0 percent), hyperuricemia (4 percent vs 2 percent), dizziness (9 percent vs 2 percent), and upper respiratory tract infection (7 percent vs 0 percent). No initial dosage ...
Hyperuricemia in Medical Definition
... 2 O Dehydration / Hypervolemia - K + Hypokalemia / Hyperkalemia - Cl − Hyperchloremia / Hypochloremia
Purine and pyrimidine
hyperuricemia - Lesch-Nyhan syndrome - Xanthinuria
Porphyrin
Acute intermittent , Gunther's , Cutanea tarda , Erythropoietic , ...
Hyperuricemia in Medical Dictionary
... that high blood levels of uric acid ( hyperuricemia ) may be a risk indicator for heart disease . ... caused by too much uric acid in the blood ( hyperuricemia ). hyperuricemia usually does no harm, and most people with high ...
... Note: hyperuricemia does not inevitably lead to gout . In fact, ... disease . Acute Gouty Arthritis ... hyperuricemia occurs most often in men and in postmenopausal ... But if untreated, it can lead to: ... hyperuricemia Excessively high levels of uric acid in the ...
... elevated levels of uric acid in the blood ( hyperuricemia ). Uric acid is a waste product formed from ... caused by too much uric acid in the blood ( hyperuricemia ). hyperuricemia usually does no harm, and most people with high ...
... Too much thyroid hormone . Symptoms include weight loss , chest pain , cramps , diarrhea , and nervousness. Also called overactive thyroid. hyperuricemia ... ...
... disease such as diabetic retinopathy ( eye disease ) or ... High blood sugar ( hyperglycemia ). Too much uric acid in the blood ( hyperuricemia ). Excess uric acid in the blood can lead to gout . Gastrointestinal problems such as upset stomach , gas, nausea , vomiting , and ...
... . Tumor lysis syndrome results from rapid breakdown of malignant cells resulting in a number of metabolic abnormalities, most notably hyperuricemia , hyperkalemia , and hyperphosphatemia. hyperkalemia - high amounts of potassium in the blood ; can be diagnose d by blood test, or by ...
... Too much thyroid hormone . Symptoms include weight loss , chest pain , cramps , diarrhea , and nervousness. Also called overactive thyroid. hyperuricemia ... Radioactive iodine used to treat hyperthyroid ism (overactive thyroid) or radiation treatment s for head or neck cancer s can destroy ...
... Too much thyroid hormone . Symptoms include weight loss , chest pain , cramps , diarrhea , and nervousness. Also called overactive thyroid. hyperuricemia ... Radioactive iodine used to treat hyperthyroidism (overactive thyroid) or radiation treatment s for head or neck cancer s can destroy the ...
... Too much thyroid hormone . Symptoms include weight loss , chest pain , cramps , diarrhea , and nervousness. Also called overactive thyroid. hyperuricemia ... ANOREXIA : Lack or loss of appetite that causes significant weight loss . ANOSCOPY : A visual examination of the anal canal with an ...
... Note: hyperuricemia does not inevitably lead to gout . In fact, ... disease . Acute Gouty Arthritis ... hyperuricemia occurs most often in men and in postmenopausal ... But if untreated, it can lead to: ... hyperuricemia Excessively high levels of uric acid in the ...
... elevated levels of uric acid in the blood ( hyperuricemia ). Uric acid is a waste product formed from ... caused by too much uric acid in the blood ( hyperuricemia ). hyperuricemia usually does no harm, and most people with high ...
... Too much thyroid hormone . Symptoms include weight loss , chest pain , cramps , diarrhea , and nervousness. Also called overactive thyroid. hyperuricemia ... ...
... disease such as diabetic retinopathy ( eye disease ) or ... High blood sugar ( hyperglycemia ). Too much uric acid in the blood ( hyperuricemia ). Excess uric acid in the blood can lead to gout . Gastrointestinal problems such as upset stomach , gas, nausea , vomiting , and ...
... . Tumor lysis syndrome results from rapid breakdown of malignant cells resulting in a number of metabolic abnormalities, most notably hyperuricemia , hyperkalemia , and hyperphosphatemia. hyperkalemia - high amounts of potassium in the blood ; can be diagnose d by blood test, or by ...
... Too much thyroid hormone . Symptoms include weight loss , chest pain , cramps , diarrhea , and nervousness. Also called overactive thyroid. hyperuricemia ... Radioactive iodine used to treat hyperthyroid ism (overactive thyroid) or radiation treatment s for head or neck cancer s can destroy ...
... Too much thyroid hormone . Symptoms include weight loss , chest pain , cramps , diarrhea , and nervousness. Also called overactive thyroid. hyperuricemia ... Radioactive iodine used to treat hyperthyroidism (overactive thyroid) or radiation treatment s for head or neck cancer s can destroy the ...
... Too much thyroid hormone . Symptoms include weight loss , chest pain , cramps , diarrhea , and nervousness. Also called overactive thyroid. hyperuricemia ... ANOREXIA : Lack or loss of appetite that causes significant weight loss . ANOSCOPY : A visual examination of the anal canal with an ...
Hyperuricemia in Biological Technology
... 40 mg and 80 mg for the chronic management of hyperuricemia in patients with gout. This once-daily, oral ... for the more than five million patients who have hyperuricemia associated with gout. ULORIC was discovered by ... offers clinicians and their patients who have hyperuricemia associated with gout a new treatment option that ...
... markets. Savient is currently developing one product: KRYSTEXXA(TM) (pegloticase) as a therapy for patients with treatment failure gout, to control hyperuricemia and to manage the signs and symptoms of gout. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, formerly ...
... 1, 2009. ABOUT KRYSTEXXA(TM) KRYSTEXXA (TM) (pegloticase) is a pegylated recombinant mammalian urate oxidase in development to control hyperuricemia and its clinical consequences in patients for whom conventional therapy is contraindicated or has been ineffective. The two Phase 3 pivotal trials ...
Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout
... normal sUA concentrations in gout patients with hyperuricemia (greater than or equal to 8.0 mg/dl). The primary ... related to rheumatology, and most frequently to hyperuricemia and gout. About Gout An estimated 3-5 million ... been approved by the FDA for the treatment of hyperuricemia associated with gout in the past 40 years. ...... markets. Savient is currently developing one product: KRYSTEXXA(TM) (pegloticase) as a therapy for patients with treatment failure gout, to control hyperuricemia and to manage the signs and symptoms of gout. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, formerly ...
... 1, 2009. ABOUT KRYSTEXXA(TM) KRYSTEXXA (TM) (pegloticase) is a pegylated recombinant mammalian urate oxidase in development to control hyperuricemia and its clinical consequences in patients for whom conventional therapy is contraindicated or has been ineffective. The two Phase 3 pivotal trials ...
Other ContentslosslosslosslosslosslosslosslosslosslossgaingaingaingaingaingaingaingaingainwestwestwestmanagementmanagementmanagementmanagementmanagementmanagementmanagementmanagementmanagementweightweightweightweightweightweightweightweightweightweightwheezingwheezingwhiteheadwhiplashwhiplashOther TagsSkipDetectiDetectiDetectiDetectiDetectiNailNailNailDeterDeterDeterDeterDeterOther Tagsinaccessible 2deficiencies 2deficiencies 3successfully 2successfully 3successfully 4successfully 5successfully 6successfully 7successfully 8successfully 9successfully 10tool 2tool 3tool 4tool 5tool 6tool 7tool 8tool 9tool 10automated 2iron 2iron 3iron 4struggle 2comes 2comes 3comes 4comes 5comes 6comes 7comes 8comes 9comes 10
(Date:11/9/2009)... , SAN DIEGO, Nov. 9 HUYA B...hina,s biopharmaceutical innovation, today announc...cine and Pharmacy, Ocean University of China. The ... that HUYA has established with China,s leading re...accelerate the global development and commercializ...
(Date:11/9/2009)... , A new study finds that women treated for breas...f they have dense breasts. Published in the Decemb...rnal of the American Cancer Society, the study,s r...ense breasts may benefit from additional therapies...s studies indicate that women with dense breast ti...
(Date:11/8/2009)... , WASHINGTON, Nov. 8 /PRNewswire-USNewswire/..., issued the following statement about the passage...s us and the American voters a lot about core valu...ur core values, seeking to overcome the struggles ...ruggles mean that many cannot afford basic healthc...
(Date:11/8/2009)... , AARP Praises House Passage of Health Care...rengthen Medicare, improve coverage for all Americ...SNewswire/ -- ,, SUMMARY: Last night the Uni...l health care reform legislation that would streng...y insurance companies that prices millions of Amer...
(Date:11/8/2009)... Ignoring pain now can take you out of the game l...althDay News) -- Foot injuries are the talk of the...back Eli Manning and running back Willie Parker. ,...sociation and American Academy of Podiatric Sports...ir feet when they play fall sports like football a...
Breaking Medicine News(10 mins):Health News:HUYA Bioscience International Establishes Strategic Partnership with School of Medicine and Pharmacy, Ocean University of China 2Health News:Breast density associated with increased risk of cancer recurrence 2Health News:Catholics for Choice Statement on Healthcare Reform Bill 2Health News:AARP Pennsylvania Key Vote News Alert 2Health News:AARP Pennsylvania Key Vote News Alert 3Health News:AARP Pennsylvania Key Vote News Alert 4Health News:Rx for Fall Foot Injuries 2[0] HUYA Bioscience International Establishes Strategic Partnership with School of Medicine and Pharmacy, Ocean University of China[0] Breast density associated with increased risk of cancer recurrence[1] Catholics for Choice Statement on Healthcare Reform Bill[1] AARP Pennsylvania Key Vote News Alert[0] Rx for Fall Foot Injuries
(Date:11/4/2009)...s out, hold the power to help militaries and munit...p toxic waste on test sites. , Compounds known a... in World War II and have been used in military mu...are often used to propel tank shells and act like ...reased knowledge of their environmentally harmful ...
(Date:11/4/2009)...s received more than $10 million in research grant...l stimulus program, bringing thetotal amount of st...illion. Thirty-three projects achieved stimulus f...ther. , "The university has thoughtfully underta...larly excellence to federal agency priorities. Th...
(Date:11/4/2009)...FirstCall/ -- Quest Diagnostics Incorporated (NYSE...ic testing, information and services, announced th... income from continuing operations rose to $192 mi...on, or $0.81 per diluted share, for the third quar...educed by a $0.03 per share charge associated with...
Breaking Biology News(10 mins):Genomic research will enable greener cleanup of military explosive test sites 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 3Quest Diagnostics Reports Strong Performance in Third Quarter 2009 2Quest Diagnostics Reports Strong Performance in Third Quarter 2009 3Quest Diagnostics Reports Strong Performance in Third Quarter 2009 4Quest Diagnostics Reports Strong Performance in Third Quarter 2009 5Quest Diagnostics Reports Strong Performance in Third Quarter 2009 6Quest Diagnostics Reports Strong Performance in Third Quarter 2009 7Quest Diagnostics Reports Strong Performance in Third Quarter 2009 8Quest Diagnostics Reports Strong Performance in Third Quarter 2009 9Quest Diagnostics Reports Strong Performance in Third Quarter 2009 10Quest Diagnostics Reports Strong Performance in Third Quarter 2009 11Quest Diagnostics Reports Strong Performance in Third Quarter 2009 12Quest Diagnostics Reports Strong Performance in Third Quarter 2009 13Quest Diagnostics Reports Strong Performance in Third Quarter 2009 14Quest Diagnostics Reports Strong Performance in Third Quarter 2009 15Quest Diagnostics Reports Strong Performance in Third Quarter 2009 16Quest Diagnostics Reports Strong Performance in Third Quarter 2009 17Unprecedented Merger Occurs in Retained Physician Search Industry 47441 1Unprecedented Merger Occurs in Retained Physician Search Industry 47441 2Unprecedented Merger Occurs in Retained Physician Search Industry 47441 3Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT 101 in Prostate Brain and Lung Cancers at 2009 ASCO Annu 12378 1Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT 101 in Prostate Brain and Lung Cancers at 2009 ASCO Annu 12378 2Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT 101 in Prostate Brain and Lung Cancers at 2009 ASCO Annu 12378 3Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT 101 in Prostate Brain and Lung Cancers at 2009 ASCO Annu 12378 4Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT 101 in Prostate Brain and Lung Cancers at 2009 ASCO Annu 12378 5Religious devotion does not impact abortion decisions of young unwed women 47440 1Religious devotion does not impact abortion decisions of young unwed women 47440 2| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |